Edition:
India

Ankur Banerjee

Regeneron to stop enrolling very sick COVID-19 patients in antibody trial

30 Oct 2020

Regeneron Pharmaceuticals said on Friday it would stop enrolling patients receiving advanced COVID-19 care in a trial testing its experimental antibody treatment in hospitalized patients, based on the recommendation of an independent safety board.

GSK warns COVID-19 will dent full-year earnings

28 Oct 2020

Britain's GSK cautioned full-year earnings would likely come in at the lower end of its forecast range after the COVID-19 pandemic took a toll on its vaccines unit, with people in the United States shunning visits to their physician for their shots.

Eli Lilly strikes optimistic tone on COVID-19 therapy after trial failure

27 Oct 2020

Eli Lilly and Co on Tuesday aimed to ease investor concerns about its COVID-19 antibody treatment after a trial of the therapy failed to show a benefit in hospitalized patients.

Pfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a vaccine is available

22 Oct 2020

Pfizer Inc and Johnson & Johnson are seeking input from a U.S. Food and Drug Administration advisory committee on retaining and attracting volunteers for COVID-19 vaccine trials after a vaccine becomes available, if they know they might receive a placebo.

Bausch Health to spin off eye care business, shares soar

06 Aug 2020

Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin off its eye care unit, Bausch + Lomb, into a separate publicly listed company, seven years after acquiring it for nearly $9 billion.

UPDATE 2-Bausch Health to spin off eye care business, shares soar

06 Aug 2020

Aug 6 Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin off its eye care unit, Bausch + Lomb, into a separate publicly listed company, seven years after acquiring it for nearly $9 billion.

Moderna prices COVID-19 vaccine at $32-$37 per dose for smaller volume deals

06 Aug 2020

Moderna Inc said on Wednesday smaller volume agreements for its experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc's vaccine candidate.

Proportion of youth with COVID-19 triples in five months: WHO

04 Aug 2020

Young people who are hitting nightclubs and beaches are leading a rise in fresh coronavirus cases across the world, with the proportion of those aged 15 to 24 who are infected rising three-fold in about five months, the World Health Organization said.

World News